EUCTR2004-000199-14-IT进行中（未招募）不适用
A Double-Blind, Randomized, Multicenter, Placebo-Controlled, In-Patient, Maximum 24 Day Study of Levetiracetam Oral Solution 20-50 mg/kg/day as Adjunctive Treatment of Refractory Partial Onset Seizures in Pediatric Epileptic Subjects Ranging in Age from 1 Month to Less Than 4 Years of Age.
CB PHARMA0 个研究点目标入组 220 人开始时间: 2007年1月15日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A placebo-Controlled,Phase III Study to Evaluate the Efficacy, Tolerability and Safety of Intramuscular Injections of PLX-PAD for the Treatment of Patients with Critical Limb Ischemia (CLI) with Minor Tissue Loss who are Unsuitable for RevascularizatioEUCTR2015-005532-18-CZPluristem Ltd.246
进行中（未招募）
1 期
A placebo-Controlled,Phase III Study to Evaluate the Efficacy, Tolerability and Safety of Intramuscular Injections of PLX-PAD for the Treatment of Patients with Critical Limb Ischemia (CLI) with Minor Tissue Loss who are Unsuitable for RevascularizatioEUCTR2015-005532-18-DEPluristem Ltd.300
进行中（未招募）
1 期
BCX9930 compared to placebo in the treatment of PNHEUCTR2020-004403-14-ITBIOCRYST PHARMACEUTICALS INC.57
进行中（未招募）
1 期
A Clinical Study to test the effect of the drug Itraconazole (PUR1900) in Adult Asthmatic Patients with Allergic Bronchopulmonary AspergillosisAsthma with Allergic Bronchopulmonary AspergillosisMedDRA version: 20.1Level: PTClassification code 10006474Term: Bronchopulmonary aspergillosis allergicSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-002949-11-GBPulmatrix, Inc.64
未知
2 期
A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel Group, 24-Week Phase 2 Study to Evaluate Efficacy and Safety of RDEA3170 5mg, 7.5mg, 10mg, 12.5mg and 15mg Versus Placebo and Open-Label Allopurinol 200mg as a Reference Arm in Japanese Patients With Gout or Asymptomatic HyperuricemiaGout and HyperuricemiaJPRN-jRCT2080222512AstraZeneca